Journal
AMERICAN JOURNAL OF MEDICINE
Volume 115, Issue -, Pages 24-28Publisher
ELSEVIER SCIENCE INC
DOI: 10.1016/j.amjmed.2003.08.011
Keywords
-
Categories
Ask authors/readers for more resources
Patients with type 2 diabetes mellitus or the metabolic syndrome have a unique dyslipidemia characterized, by hypertriglyceridemia; elevated blood levels of apolipoprotein B; small, dense low-density lipoprotein (LDL) cholesterol; and low levels of high-density lipoprotein (HDL) cholesterol, in particular HDL2-C. Treatment of the dyslipidemia associated with these disorders should focus on correcting the abnormal lipoprotein levels as well as LDL and HDL heterogeneity. Statins and fibrates are useful for treating elevated LDL in patients with and without diabetes or the metabolic syndrome. In addition, thiazolidinediones or niacin in combination with a statin show promise for correcting defects in LDL and HDL heterogeneity. The ultimate goal of treatment in this patient population is to prevent the development and progression of coronary artery disease. (C) 2003 by Excerpta Medica, Inc.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available